Daily Updates
The Iran War Is Now Hitting Pharma Supply Chains Directly
The Iran war’s impact on pharmaceutical supply chains is no longer theoretical. Evonik, a major supplier of pharma-grade amino and keto acids, announced a 15%
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The Iran war’s impact on pharmaceutical supply chains is no longer theoretical. Evonik, a major supplier of pharma-grade amino and keto acids, announced a 15%
It’s over. FDA Commissioner Marty Makary resigned on Tuesday after 13 months in the role. The resignation followed days of reporting that the White House
Three deals worth a combined $19.5 billion were announced in a single day. Bristol Myers Squibb formed the largest China-to-West licensing partnership in biopharma history,
Daiichi Sankyo’s five-year plan is the most ambitious oncology roadmap any Japanese pharma company has ever published. The company is betting everything on antibody-drug conjugates,
This is the most consequential FDA leadership story since Makary took office. On Friday afternoon, the Wall Street Journal reported that President Trump was planning
GSK is making a deliberate choice not to compete in the GLP-1 weight-loss race. Instead, the company is building a cardiometabolic strategy around the complications
The oral GLP-1 race has its first scoreboard, and it is not close. Novo Nordisk’s Wegovy pill brought in $354 million (DKK 2.26 billion) in
Novo Nordisk made its most significant commercial move of the year two days before reporting Q1 earnings. The company launched oral Ozempic—a rebrand of the
The mifepristone ruling matters far beyond reproductive health. On Friday, the 5th Circuit Court of Appeals reinstated a nationwide in-person dispensing requirement for mifepristone, overriding
Biopharma M&A reached $84 billion in Q1 2026, the strongest start to a year since 2019, according to Dealogic data cited by Reuters. If the